[1]叶 亮,李运泽,彭继承,等.血清Cys-C、α1-MG联合检测在早期肝肾综合征诊断中的意义[J].医学信息,2022,35(16):67-69.[doi:10.3969/j.issn.1006-1959.2022.16.014]
　YE Liang,LI Yun-ze,PENG Ji-cheng,et al.Significance of Combined Detection of Serum Cys-C and α1-MG in Diagnosis of Early Hepatorenal Syndrome[J].Journal of Medical Information,2022,35(16):67-69.[doi:10.3969/j.issn.1006-1959.2022.16.014]
点击复制

血清Cys-C、α1-MG联合检测在早期肝肾综合征诊断中的意义()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年16期
页码:
67-69
栏目:
论著
出版日期:
2022-08-15

文章信息/Info

Title:
Significance of Combined Detection of Serum Cys-C and α1-MG in Diagnosis of Early Hepatorenal Syndrome
文章编号:
1006-1959（2022）16-0067-03
作者:
叶 亮; 李运泽; 彭继承; 等
（广西医科大学附属柳州市人民医院消化内科，广西 柳州 545000）
Author(s):
YE Liang; LI Yun-ze; PENG Ji-cheng; et al.
(Department of Gastroenterology,Affiliated Liuzhou People’s Hospital of Guangxi Medical University,Liuzhou 545000,Guangxi,China)
关键词:
肝肾综合征; 胱抑素C; α1微球蛋白
Keywords:
Hepatorenal syndrome; Cystatin C; α1-microglobulin
分类号:
R575
DOI:
10.3969/j.issn.1006-1959.2022.16.014
文献标志码:
A
摘要:
目的 探讨胱抑素C（Cys-C）、α1微球蛋白（α1-MG）在诊断早期肝肾综合征中的价值及意义。方法 选取2018年3月-2021年5月我院收治的肝硬化失代偿患者40例设为肝硬化失代偿组，肝肾综合征患者40例设为肝肾综合征组。比较两组Cys-C、α1-MG水平，采用受试者工作特征（ROC）曲线分析Cys-C、α1-MG两者单独及联合诊断肝肾综合征的效能。结果 肝肾综合征组Cys-C、α1-MG水平高于肝硬化失代偿组，差异有统计学意义（P＜0.05）。ROC曲线分析显示，Cys-C+α1-MG诊断肝肾综合征的AUC高于Cys-C、α1-MG单独诊断，且联合诊断的敏感性及阴性预测值高于Cys-C、α1-MG单独诊断。结论 Cys-C、α1-MG联合诊断肝肾综合征的预测价值高于单一指标，可作为肝肾综合征早期诊断的重要指标之一。
Abstract:
Objective To investigate the value and significance of cystatin C (Cys-C) and α1-microglobulin (α1-MG) in the diagnosis of early hepatorenal syndrome.Methods Forty patients with decompensated cirrhosis admitted to our hospital from March 2018 to May 2021 were selected as decompensated cirrhosis group, and 40 patients with hepatorenal syndrome were selected as hepatorenal syndrome group. The levels of Cys-C and α1-MG were compared between the two groups. The receiver operating characteristic (ROC) curve was used to analyze the efficacy of Cys-C and α1-MG alone and in combination in the diagnosis of hepatorenal syndrome.Results The levels of Cys-C and α1-MG in hepatorenal syndrome group were higher than those in decompensated cirrhosis group (P<0.05). ROC curve analysis showed that the AUC of Cys-C+α1-MG in the diagnosis of hepatorenal syndrome was higher than that of Cys-C and α1-MG alone, and the sensitivity and negative predictive value of combined diagnosis were higher than those of Cys-C and α1-MG alone.Conclusion The predictive value of Cys-C and α1-MG combined diagnosis of hepatorenal syndrome is higher than that of single index, which can be used as one of the important indexes for early diagnosis of hepatorenal syndrome.

参考文献/References:

[1]Sheng XY,Lin FY,Wu J,et al.Development and validation of a prognostic model for patients with hepatorenal syndrome: A retrospective cohort study[J].World J Gastroenterol,2021,27(20):2615-2629. [2]薛顺和,张锦,陈兰兰,等.胱抑素C和β2微球蛋白联合检测在肝硬化合并不同类型肾损伤中的诊断效能[J].中国肝脏病杂志(电子版),2020,12(3):65-71.[3]Deep A,Saxena R,Jose B.Acute kidney injury in children with chronic liver disease[J].Pediatr Nephrol,2019,34(1):45-59.[4]刘沁雨,李海.肝肾综合征临床诊断标准的变迁及新的肾损伤指标在肝硬化患者中的应用[J].临床肝胆病杂志,2018,34(6):1308-1312.[5]Bashir MH,Iqbal S,Miller R,et al.Management and outcomes of hepatorenal syndrome at an urban academic medical center: a retrospective study[J].Eur J Gastroenterol Hepatol,2019,31:1545-1549[6]Wong F.Acute kidney injury in liver cirrhosis: new definition and application[J].Clin Mol Hepatol,2016,22(4):415-422.[7]胡掌朝,白雪,程帅师,等.奥曲肽辅助特利加压素在肝硬化失代偿期并发肝肾综合征治疗中的疗效[J].肝脏,2020,25(12):1294-1296.[8]Facciorusso A,Chandar AK,Murad MH,et al.Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis[J].Lancet Gastroenterol Hepatol,2017,2(2):94-102.[9]Angeli P,Ginès P,Wong F,et al.Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites[J].J Hepatol,2015,62(4):968-974. [10]Modi RM,Patel N,Metwally SN,et al.Outcomes of liver transplantation in patients with hepatorenal syndrome[J].World J Hepatol,2016,8(24):999-1011. [11]高攀,朱祖安.胱抑素C对失代偿期肝硬化患者并发肝肾综合征的预测价值[J].胃肠病学和肝病学杂志,2019,28(1):101-104.[12]Akda GT,Uca AU.Cystatin C as a potential biomarker to evaluate migraine[J].Arq Neuropsiquiatr,2020,78(6):337-341.[13]Gupta K,Rani P,Rohatgi A,et al.Noradrenaline for reverting hepatorenal syndrome:a prospective,observational,single-center study[J].Clin Exp Gastroenterol,2018,11:317-324.[14]覃天资,黄群,吴军,等.血清Hcy、Cys-C、β2-MG及α1-MG在高尿酸血症肾结石患者中的表达及意义[J].广州医药,2019,50(6):34-38.[15]Ikeda M,Ezaki T,Tsukahara T,et al.Critical evaluation of alpha1- and beta2-microglobulins in urine as markers of cadmium-induced tubular dysfunction[J].Biometals,2004,17(5):539-541.[16]Stefanovic V,Djukanovic L,Cukuranovic R,et al.Beta2-microglobulin and alpha1-microglobulin as markers of Balkan endemic nephropathy, a worldwide disease[J].Ren Fail,2011,33(2):176-183. [17]Jiang X,Zhang Q,Wang HB,et al.Associations of urinary, glomerular, and tubular markers with the development of diabetic kidney disease in type 2 diabetes patients[J].J Clin Lab Anal,2018,32(1):e22191.[18]纪桂贤,高福来,付丽坤,等.血清Cys C、β2-MG联合尿α1-MG、β2-MG在亚临床肝肾综合征诊断中的意义[J].胃肠病学和肝病学杂志,2017,26(7):802-804.[19]潘枭,杨阳.尿液α1-MG与血清β2-MG、TRF、Cys-C检测在早期诊断慢性肾小球肾炎中的临床价值[J].哈尔滨医药,2021,41(3):38-39.[20]刘琳,李林英,潘柏莉,等.尿液α1-MG联合血清β2-MG、Cys-C检测在慢性肾小球肾炎早期诊断中的价值[J].检验医学与临床,2018,15(22):3408-3410,3414.[21]雷蕾,李良平,张虎.血清胱抑素C联合尿中性粒细胞明胶酶相关脂质运载蛋白对肝硬化腹水继发急性肾损伤的诊断价值[J].临床肝胆病杂志,2018,34(1):101-105.[22]Gharaibeh KA,Hamadah AM,El-Zoghby ZM,et al.Cystatin C Predicts Renal Recovery Earlier Than Creatinine Among Patients With Acute Kidney Injury[J].Kidney Int Rep,2017,3(2):337-342.

相似文献/References:

[1]李 艳.胱抑素C临床检验及对诊断肾脏疾病的临床价值[J].医学信息,2018,31(04):42.[doi:10.3969/j.issn.1006-1959.2018.04.014]
　LI Yan.Clinical Test of Cystatin C and its Clinical Value in the Diagnosis of Renal Diseases[J].Journal of Medical Information,2018,31(16):42.[doi:10.3969/j.issn.1006-1959.2018.04.014]
[2]祁兴顺,周新苗,许向波,等.肝硬化患者应用特利加压素治疗期间发生 低钠血症的现状研究[J].医学信息,2018,31(09):1.[doi:10.3969/j.issn.1006-1959.2018.09.001]
[3]黄秋菊.胱抑素C及脂蛋白α在早期糖尿病肾病诊断中的价值研究[J].医学信息,2018,31(14):57.[doi:10.3969/j.issn.1006-1959.2018.14.018]
　HUANG Qiu-ju.The Value of Cystatin C and Lipoprotein α in the Diagnosis of Early Diabetic Nephropathy[J].Journal of Medical Information,2018,31(16):57.[doi:10.3969/j.issn.1006-1959.2018.14.018]
[4]熊武芳,杨 娜,肖光军,等.同一厂家两种胱抑素C检测试剂盒的性能验证及其 检测结果的一致性[J].医学信息,2018,31(15):55.[doi:10.3969/j.issn.1006-1959.2018.15.018]
　XIONG Wu-fang,YANG Na,XIAO Guang-jun,et al.Performance Verification of Two Cystatin C Test Kits and Consistency of Test Results from the Same Manufacturer[J].Journal of Medical Information,2018,31(16):55.[doi:10.3969/j.issn.1006-1959.2018.15.018]
[5]韩佳妮.参芪地黄汤治疗早期糖尿病肾病的疗效[J].医学信息,2019,32(22):139.[doi:10.3969/j.issn.1006-1959.2019.22.047]
　HAN Jia-ni.Effect of Shenqi Dihuang Decoction in Treating Early Diabetic Nephropathy[J].Journal of Medical Information,2019,32(16):139.[doi:10.3969/j.issn.1006-1959.2019.22.047]
[6]伊学军,翟建新.胱抑素C检测及其在肾脏相关疾病中的应用[J].医学信息,2020,33(04):55.[doi:10.3969/j.issn.1006-1959.2020.04.017]
　YI Xue-jun,ZHAI Jian-xin.Cystatin C Detection and its Application in Kidney-related Diseases[J].Journal of Medical Information,2020,33(16):55.[doi:10.3969/j.issn.1006-1959.2020.04.017]
[7]段宗宝,肖三法,罗惠群.环磷酰胺联合氢氯噻嗪治疗2型糖尿病肾病的临床研究[J].医学信息,2021,34(23):159.[doi:10.3969/j.issn.1006-1959.2021.23.048]
　DUAN Zong-bao,XIAO San-fa,LUO Hui-qun.Clinical Study of Cyclophosphamide Combined with Hydrochlorothiazide in the Treatment of Type 2 Diabetic Nephropathy[J].Journal of Medical Information,2021,34(16):159.[doi:10.3969/j.issn.1006-1959.2021.23.048]
[8]马 燕,王晓忠,延国威,等.乙肝肝硬化低血钠症患者血清钠、肌酐以及胱抑素C与肾功能损害程度的关系[J].医学信息,2020,33(19):55.[doi:10.3969/j.issn.1006-1959.2020.19.017]
　MA Yan,WANG Xiao-zhong,YAN Guo-wei,et al.The Relationship Between Serum Sodium,Creatinine,Cystatin C and the Degree of Renal Damage in Patients with Hepatitis B Liver Cirrhosis and Hyponatremia[J].Journal of Medical Information,2020,33(16):55.[doi:10.3969/j.issn.1006-1959.2020.19.017]
[9]姚安琪,郑艳辉.托伐普坦治疗肾脏疾病的应用[J].医学信息,2020,33(24):53.[doi:10.3969/j.issn.1006-1959.2020.24.015]
　YAO An-qi,ZHENG Yan-hui.Application of Tolvaptan in Treating Kidney Disease[J].Journal of Medical Information,2020,33(16):53.[doi:10.3969/j.issn.1006-1959.2020.24.015]
[10]舒霁坤,沈学耕.慢性心力衰竭患者炎症细胞因子水平与心室重构的相关性分析[J].医学信息,2022,35(02):100.[doi:10.3969/j.issn.1006-1959.2022.02.024]
　SHU Ji-kun,SHEN Xue-geng.Correlation Between Inflammatory Cytokines and Ventricular Remodelingin Patients with Chronic Heart Failure[J].Journal of Medical Information,2022,35(16):100.[doi:10.3969/j.issn.1006-1959.2022.02.024]

更新日期/Last Update: 1900-01-01